Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1]
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al..
Peginterferon alfa-2a and ribavirin in patients who have failed previous treatment..
Gastroenterology. , 126 (2004), pp. 1015-23
[2]
Bonkovsky HL, Naishadman D, Lambretch RW, Cheng RT, Hoefs JC, Nash SR, et al..
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C..
Gastroenterology. , 131 (2006), pp. 1440-51
[3]
Shiffman M, Ghany MG, Morgan TR, Wright E, Everson G, Lindsay K, et al..
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C..
Gastroenterology. , 132 (2007), pp. 103-12
[4]
Poynard T, Schiff E, Terg R, Goncales F, Diago M, Reichen J, et al..
Sustained virological response in the EPIC3 trial: week 12 virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG Intron/Rebetol weight based dosing, J Hepatology..
, 42 Suppl 2 (2005), pp. 40 (abstract)
[5]
Jacobson IM, Gonzales SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, et al..
A randomized trial of pegylated interferon alfa-2b plus ribavirin in the retreatment of chronic hepatitis C..
Am J Gastroenterol. , 100 (2005), pp. 2453-62
[6]
Krawit EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD; New York New England Study Team..
Peginterferon alfa 2b and ribavirin for treatment of refractory chronic hepatitis C..
J Hepatology. , 43 (2005), pp. 243-9
[7]
Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al..
Pegylated interferon alfa-2b plus ribavirin in the treatment of interferon-ribavirin nonresponders..
Gastroenterology. , 130 (2006), pp. 1098-106
[8]
Basso M, Torre F, Grasso A, Percario G, Azzola E, Artioli S, et al..
Pegylated interferon and ribavirin in re-treatment of responder-relapser patients..
Dig Liver Dis. , 39 (2007), pp. 47-51
[9]
Poynard T, Schiff E, Terg R, Goncales F, Diago M, Reichen J, et al..
HCV-RNA negativity after 12 weeks of therapy is the best predictor of sustained virological response in the retreatment of previous interferon alfa/ribavirin non responders:Results from the EPIC3 program..
Hepatology. , 44 Suppl 1 (2006), pp. 606A (Abstract)
[10]
Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, et al..
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy..
J Hepatology. , 46 (2007), pp. 596-604
[11]
Diago M, Crespo J, Olveira A, Pérez R, Bárcena R, Sánchez-Tapias JM, et al..
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alfa-2a in hepatitis C virus genotype 1 true non-responder patients..
Aliment Pharmacol Ther. , 26 (2007), pp. 1131-8
[12]
Jensen DM, Freilich B, Andreone P, DiBisceglie A, Brandão-Mello CE, Reddy K, et al..
Pegylated interferon alfa-2a (40 kd) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12 kd)/ (RBV): final efficacy and safety outcomes of the REPEAT study..
58 Annual Meeting of the AASL, Boston 2007. , (Abstract LB4),
[13]
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, et al..
Peginterferon alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable HCV-RNA at week 4 of treatment..
Gastroenterology. , 131 (2006), pp. 451-60
[14]
Bacon B, Regev A, Galib RH, Morelli G, Rothstein KD, Shiffman ML, et al..
The DIRECT trial (Daily-dose consensus interferon and ribavirin: efficacy of combined therapy): treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data..
Hepatology. , 46 Suppl1 (2007), pp. 311A-312A
[15]
Nelson DR, Rutsgi VK, Balan V, Sulkowski M, Davis GL, Muir A, et al..
Sustained virological response with albinterferon alfa-2b /ribarin treatment in prior interferon therapy non-responders..
Hepatology. , 46 Suppl 1 (2007), pp. 256A
[16]
Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al..
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C..
Hepatology. , 32 (2000), pp. 1131-7
[17]
Rincón D, Ripoll C, Iacono OL, Salcedo M, Catalina MV, Álvarez E, et al..
Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis..
Am J Gastroenterol. , 101 (2006), pp. 2269-74
[18]
Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al..
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia..
Gastroenterology. , 117 (1999), pp. 1164-72
[19]
Kaiser S, Lutze B, Sauter B, Bissinger L, Werner C, Hass H, et al..
Long-term low dose treatment with pegylated interferon alpha 2b leads to a significant reduction in fibrosis and inflammatory score in chronic hepatitis C non-responder patients with fibrosis or cirrhosis..
Hepatology. , 46 Suppl 1 (2007), pp. 820A
[20]
Curry M, Cárdenas A, Afdhal N..
Effect of maintenance PEGIntron therapy on portal hypertension and its complications: results of the COPILOT study..
J Hepatol. , 42 Suppl 2 (2005), pp. 40
[21]
DiBisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al..
Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial..
Hepatology. , 46 Suppl 1 (2007), pp. 290A
